The Role of Inflammasome in Cancers and Potential Therapeutic Targets
- 1 October 2025
- book chapter
- Published by Springer Nature
- p. 749-789
Abstract
No abstract availableKeywords
This publication has 222 references indexed in Scilit:
- Anticancer activities of parthenolide in primary effusion lymphoma preclinical modelsMolecular Carcinogenesis, 2021
- Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathwayCancer Medicine, 2019
- Highly‐expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β‐catenin and mTOR/HIF1α/VEGF signalingInternational Journal of Cancer, 2019
- MicroRNA‐22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3Journal of Cellular Physiology, 2018
- Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer developmentJournal of Medical Virology, 2016
- Interleukin (IL)‐18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursorInternational Journal of Cancer, 2010
- Immunomodulatory IL‐18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor statusInternational Journal of Cancer, 2010
- A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco‐associated cancers, lung and bladder cancer, by targeting NF‐κB and generating reactive oxygen speciesInternational Journal of Cancer, 2010
- A water‐soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFκB and generating reactive oxygen speciesThe Prostate, 2010
- Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis #Hepatology, 2009